Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain.
Chronic treatment of rats with the neuroleptic drugs haloperidol, fluphenazine, and reserpine elicits a 20 to 25% increase in striatal dopamine receptor binding assayed with [3H]haloperidol. This increase in receptor sites may account for behavioral supersensitivity to dopamine receptor stimulants in such animals and for tardive dyskinesia in patients treated with these drugs.
D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D003342:Corpus Striatum / Q000378:metabolism*; D003913:Dextroamphetamine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005476:Fluphenazine / Q000494:pharmacology; D006220:Haloperidol / Q000378:metabolism / Q000494:pharmacology; D007700:Kinetics; D051381:Rats; D011954:Receptors, Dopamine / Q000378:metabolism*; D012110:Reserpine / Q000494:pharmacology; D013997:Time Factors; D014149:Tranquilizing Agents / Q000494:pharmacology*
D011954:Receptors, Dopamine; D014149:Tranquilizing Agents; D012110:Reserpine; D006220:Haloperidol; D001058:Apomorphine; D005476:Fluphenazine; D003913:Dextroamphetamine